Brief: Basilea Pharmaceutica AG Allschwil - Partners Oncology Drug Candidate Lisavanbulin With Glioblastoma Foundation

Basilea Pharmaceutica AG, Allschwil

20/06/2024 06:18

June 20 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL
 BSLN.S :
    * BASILEA PARTNERS ONCOLOGY DRUG CANDIDATE LISAVANBULIN WITH
GLIOBLASTOMA FOUNDATION
    * UNDER TERMS OF AGREEMENT, BASILEA SELLS AND TRANSFERS ALL
RIGHTS
TO LISAVANBULIN TO GLIOBLASTOMA FOUNDATION FOR AN UNDISCLOSED
INITIAL PURCHASE PRICE
    * BASILEA WILL PARTICIPATE IN FUTURE PROCEEDS FROM ANY
POTENTIAL
COMMERCIAL PARTNERSHIPS AT A FIXED DOUBLE-DIGIT PERCENTAGE

Source text for Eikon:  ID:nGNEj0Z0x 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com))